All the news Showing 10 of 111 articles from: Disease course and symptomsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources New EASL hepatitis C recommendations emphasise simplicity Liz Highleyman / 23 April 2018 The European Association for the Study of the Liver (EASL) released its latest hepatitis C treatment recommendations at the 2018 International Liver Congress this month in Paris. The guidelines are available online in ... Secondary liver cancer after colorectal cancer more common in people with chronic hepatitis B Keith Alcorn / 22 January 2018 The spread of cancer from the bowel to the liver – metastasis – is more likely to occur in people with chronic hepatitis B infection, a Chinese study published in ... Nivolumab improves outcomes in liver cancer study Liz Highleyman / 13 November 2017 Nivolumab (Opdivo), a PD-1 checkpoint inhibitor that helps the immune system fight cancer, was associated with a decrease in tumour size or disease stabilisation in people with hepatocellular carcinoma (HCC) in the CheckMate ... Curing hepatitis C with DAAs linked to 71% reduction in liver cancer Liz Highleyman / 30 October 2017 People who achieved a sustained response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, ... Rapid fibrosis progression in large proportion of HIV-positive gay men after acute HCV Michael Carter / 11 October 2017 Over a third of HIV-positive gay men develop significant liver fibrosis after an episode of acute hepatitis C virus (HCV) infection, German investigators report in the Journal of Viral Hepatitis. ... Cenicriviroc may reduce fibrosis in people with fatty liver disease Liz Highleyman / 05 October 2017 Cenicriviroc, a drug that blocks both CCR5 and CCR2 receptors on immune cells, was associated with a decrease in liver fibrosis in people with non-alcoholic steatosis, a type of fatty ... Drinking three or more cups of coffee a day halves the risk of dying for people with HIV/HCV co-infection Michael Carter / 03 October 2017 Drinking three or more cups of coffee a day halves the risk of death from any cause for people with HIV/hepatitis C virus (HCV) co-infection, French investigators report in the ... Liver fibrosis speeds up around the menopause in women with HIV and HCV co-infection Michael Carter / 22 August 2017 Menopause is associated with accelerated liver fibrosis in women with HIV and hepatitis C virus (HCV) co-infection, investigators from the United States report in the online edition of Clinical Infectious Diseases. The study showed ... People with HIV are at risk for liver fibrosis and steatosis Michael Carter / 21 August 2017 Metabolic syndrome, type 2 diabetes and obesity are risk factors for the development of liver fibrosis and steatosis (liver fat accumulation) in people living with HIV, including those who do ... Switching from efavirenz to raltegravir leads to significant improvements in fatty liver disease in people with HIV Michael Carter / 17 August 2017 Switching to raltegravir from efavirenz is associated with significant improvements in liver steatosis for HIV-positive people with non-alcoholic fatty liver disease, Spanish investigators report in the online edition of Clinical ... ← Prev12345...12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive